TFF Pharmaceuticals, Inc. (TFFP)
- Previous Close
2.0600 - Open
2.0700 - Bid 2.0100 x 100
- Ask 2.1500 x 100
- Day's Range
2.0500 - 2.1100 - 52 Week Range
1.5400 - 15.9500 - Volume
6,930 - Avg. Volume
43,968 - Market Cap (intraday)
6.382M - Beta (5Y Monthly) 1.44
- PE Ratio (TTM)
-- - EPS (TTM)
-9.3800 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
tffpharma.comRecent News: TFFP
Performance Overview: TFFP
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TFFP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TFFP
Valuation Measures
Market Cap
6.50M
Enterprise Value
3.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.01
Price/Book (mrq)
1.23
Enterprise Value/Revenue
22.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-75.71%
Return on Equity (ttm)
-130.94%
Revenue (ttm)
733.87k
Net Income Avi to Common (ttm)
-21.24M
Diluted EPS (ttm)
-9.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
5.48M
Total Debt/Equity (mrq)
1.21%
Levered Free Cash Flow (ttm)
-8.75M